Want to find your lens? Five questions, no jargon — they tell you which of four reads fits how you already think.
A wonderful business — priced for growth it hasn't delivered.
A great company, but no margin of safety at this price. Worth watching, not worth buying here.
The five checks
2 good · 2 caution · 1 warning
- WarningOvervaluedFair value ~$66 vs $103 — trading 36% above what the math supports.
- CautionPrice assumes a modest step-upPriced for ~10%/yr vs a 5.8%/yr record — a stretch, not heroic.
- GoodRevenue still growingUp 8.4% last year — demand isn't the problem.
- GoodCash flow compoundingFree cash flow up ~5.8%/yr — the engine is growing.
- CautionManageable net debtNet debt of $19B — about 3.5× annual free cash flow. Normal for a mature company.
Price against fair value
What today's price assumes
Hold the price fixed and work backwards: how fast would free cash flow have to grow for $103 to make sense?
Price assumes a modest step-up.
How fair value is calculated
No analyst forecasts, no black box, no AI. Six lines from the filing to the answer.
- Free cash flow, FY26Operating cash flow less capital spending, from the annual report$5.4B
- Ten years of it, growing 5% a year, each counted 9% lessThe same growth and discount for every company$44.5B
- Everything after year tenGrowing 2.5% a year, counted the same way+ $58.9B
- The business, in today's money$103.4B
- Subtract net debtBorrowings and finance leases less cash and securities− $18.7B
- Divide by the shares on file÷ 1.2881B
Fair value per share$66
If our assumptions are wrong
Fair value per share under a faster or slower decade, and a gentler or harsher discount. The corners are where the $45 to $97 range comes from.
| 3% growth | 5% growth | 7% growth | |
|---|---|---|---|
| 8% discount | $67 | $81 | $97 |
| 9% discount | $54 | $66 | $79 |
| 10% discount | $45 | $55 | $65 |
The blue cell is the published method. Every cell sits below today’s price.
Free cash flow, ten years
$ billions · Form 10-K
What the math is really telling you. Watch whether cash flow is compounding — that, more than any single year, is what a value read hangs on.
How this was built. Every figure is computed from Medtronic plc's SEC filings — no estimates, no AI. Two-stage DCF: 9% discount rate, 5% free-cash-flow growth for 10 years, 2.5% terminal. Free cash flow is operating cash flow less capital spending. Net cash is cash and marketable securities less borrowings, commercial paper and finance leases; operating leases are disclosed but never counted as debt. We subtract net debt from the value of the business — for Medtronic that is about $19B, or $15 per share. Fundamentals are from the FY26 annual report and change only when a new one is filed. Price of $102.86 taken 2026-11-15 (Google Finance, manual entry, 2026-11-13) — it is not live and does not move during the day.
Read Medtronic another way
TickerMath is an educational tool, not investment advice — it computes one model from SEC filings and can be wrong. How we compute this →